10-Q: Neuronetics Reports Q1 2025 Results, Revenue Jumps 84% Following Greenbrook Acquisition

Neuronetics' Q1 2025 revenue increased by 84% year-over-year, driven by the acquisition of Greenbrook, though net losses also widened.

Summary

• Neuronetics reported an 84% increase in revenue for the three months ended March 31, 2025, reaching $32.0 million compared to $17.4 million in the same period of 2024.
• The increase is primarily attributed to the inclusion of clinic revenue following the acquisition of Greenbrook TMS Inc.
• The company's net loss for the quarter was $12.7 million, compared to a net loss of $7.9 million for the same period last year.
• As of March 31, 2025, Neuronetics had cash and cash equivalents of $20.2 million and an accumulated deficit of $432.5 million.
• The company's operating expenses increased due to the addition of Greenbrook's expenses.
• Neuronetics is focused on expanding its sales and customer support team and continuing research and development efforts.
• The company believes its cash and anticipated revenues are sufficient to fund operations for at least the next 12 months.
• The company completed a secondary public offering of common stock on February 10, 2025, raising net proceeds of $18.9 million.
• The company is monitoring macroeconomic impacts, including inflation and potential recessionary pressures.
• The company is in compliance with the covenants under the Perceptive Facility as of March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While revenue growth is positive, increased losses and accumulated deficit temper the outlook. The company's belief that it can fund operations for the next 12 months provides some reassurance.

Positives

• Significant revenue growth of 84% driven by the Greenbrook acquisition.
• Successful completion of a public offering, raising $18.9 million.
• The company believes its cash and anticipated revenues are sufficient to fund operations for at least the next 12 months.
• The company is in compliance with the covenants under the Perceptive Facility as of March 31, 2025.
• The company has treated over 202,318 global patients with over 7.4 million treatment sessions through March 31, 2025.

Negatives

• Net losses increased to $12.7 million for the quarter.
• Accumulated deficit stands at $432.5 million.
• Gross margin decreased from 75.1% to 49.2% due to the inclusion of Greenbrook's clinic business and reduction in treatment session revenue.
• The company incurred negative cash flows from operating activities of $17.0 million for the three months ended March 31, 2025.

Risks

• The company has incurred operating losses since its inception and anticipates that its operating losses will continue in the near term.
• The company's ability to meet its liquidity needs is dependent on growth in existing and acquired product lines and the realization of synergies subsequent to its acquisition of Greenbrook.
• Adverse global economic conditions could have a negative effect on the company's business, results of operations and financial condition and liquidity.
• The company is subject to various audits from government agencies including Medicaid and Medicare which involve the potential recoupment of reimbursements received from these agencies.

Future Outlook

Management believes that the company's cash and cash equivalents as of March 31, 2025 and anticipated revenues from sales of our products and services are sufficient to fund the company's operations for at least the next 12 months from the issuance of these consolidated financial statements.

Industry Context

The company believes it is the market leader in TMS therapy based on over 202,318 global patients treated with over 7.4 million of our treatment sessions through March 31, 2025.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies beyond stating that Neuronetics believes it is the market leader in TMS therapy.
• Without more detailed information, a comprehensive assessment against global benchmarks is not possible.

Legal Proceedings

• The company is subject from time to time to various claims and legal actions arising during the ordinary course of its business.
• The company is subject to various audits from government agencies including Medicaid and Medicare which involve the potential recoupment of reimbursements received from these agencies.

Stakeholder Impact

• Shareholders may be concerned about the increased net losses despite revenue growth.
• Employees may be affected by the integration of Greenbrook and any associated restructuring.
• Customers and patients should benefit from the expanded network of treatment centers following the Greenbrook acquisition.

Next Steps

• The company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.
• The company expects to continue to expand its direct sales and customer support team to further penetrate the market.
• The company is in the process of reviewing the internal control structure of Greenbrook and, if necessary, will make appropriate changes as we continue to integrate Greenbrook into our overall internal control over financial reporting process.

Key Dates

Keywords

Neuronetics, Greenbrook, TMS, NeuroStar, Revenue, Acquisition, Depression, Therapy, Financial Results, MDD